311 related articles for article (PubMed ID: 11383486)
21. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
Jenkins PJ; Akker S; Chew SL; Besser GM; Monson JP; Grossman AB
Clin Endocrinol (Oxf); 2000 Dec; 53(6):719-24. PubMed ID: 11155094
[TBL] [Abstract][Full Text] [Related]
22. Sandostatin LAR in acromegalic patients: long-term treatment.
Fløgstad AK; Halse J; Bakke S; Lancranjan I; Marbach P; Bruns C; Jervell J
J Clin Endocrinol Metab; 1997 Jan; 82(1):23-8. PubMed ID: 8989226
[TBL] [Abstract][Full Text] [Related]
23. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.
Davies PH; Stewart SE; Lancranjan L; Sheppard MC; Stewart PM
Clin Endocrinol (Oxf); 1998 Mar; 48(3):311-6. PubMed ID: 9578821
[TBL] [Abstract][Full Text] [Related]
24. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly.
Biermasz NR; Pereira AM; Smit JW; Romijn JA; Roelfsema F
Growth Horm IGF Res; 2005 Jun; 15(3):200-6. PubMed ID: 15935982
[TBL] [Abstract][Full Text] [Related]
25. Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients.
Invitti C; Fatti L; Camboni MG; Porcu L; Danesi L; Delitala G; Cavagnini F
J Endocrinol Invest; 1996 Sep; 19(8):548-55. PubMed ID: 8905479
[TBL] [Abstract][Full Text] [Related]
26. Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995).
Caron P; Cogne M; Gusthiot-Joudet B; Wakim S; Catus F; Bayard F
Eur J Endocrinol; 1995 Mar; 132(3):320-5. PubMed ID: 7889181
[TBL] [Abstract][Full Text] [Related]
27. [Estimation of efficacy of the octreotide LAR administration in the patients with somatotropinoma].
Waśko R; Bolko P; Kostrzewski J; Horst-Sikorska W; Liebert W; Sowiński J
Pol Arch Med Wewn; 2001 Aug; 106(2):693-8. PubMed ID: 11926144
[TBL] [Abstract][Full Text] [Related]
28. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
29. Growth hormone binding protein and growth hormone availability in acromegalic patients treated with long-acting octreotide (Sandostatin-LAR).
Fisker S; Kaal A; Montini M; Pedroncelli A; Pagani G; Orskov H
Eur J Endocrinol; 1997 Jan; 136(1):61-6. PubMed ID: 9037128
[TBL] [Abstract][Full Text] [Related]
30. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients.
van Thiel SW; Romijn JA; Biermasz NR; Ballieux BE; Frölich M; Smit JW; Corssmit EP; Roelfsema F; Pereira AM
Eur J Endocrinol; 2004 Apr; 150(4):489-95. PubMed ID: 15080778
[TBL] [Abstract][Full Text] [Related]
31. Can we predict long-term remission after somatostatin analog withdrawal in patients with acromegaly? Results from a multicenter prospective trial.
Vilar L; Fleseriu M; Naves LA; Albuquerque JL; Gadelha PS; dos Santos Faria M; Nascimento GC; Montenegro RM; Montenegro RM
Endocrine; 2014 Aug; 46(3):577-84. PubMed ID: 24272601
[TBL] [Abstract][Full Text] [Related]
32. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM
J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
[TBL] [Abstract][Full Text] [Related]
33. Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group.
Lancranjan I; Atkinson AB
Pituitary; 1999; 1(2):105-14. PubMed ID: 11081188
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy.
Ayuk J; Stewart SE; Stewart PM; Sheppard MC;
Clin Endocrinol (Oxf); 2004 Mar; 60(3):375-81. PubMed ID: 15009004
[TBL] [Abstract][Full Text] [Related]
35. Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying?
Ramírez C; Vargas G; González B; Grossman A; Rábago J; Sosa E; Espinosa-de-Los-Monteros AL; Mercado M
Eur J Endocrinol; 2012 Jan; 166(1):21-6. PubMed ID: 21993154
[TBL] [Abstract][Full Text] [Related]
36. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
[TBL] [Abstract][Full Text] [Related]
37. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?
Cozzi R; Attanasio R; Montini M; Pagani G; Lasio G; Lodrini S; Barausse M; Albizzi M; Dallabonzana D; Pedroncelli AM
J Clin Endocrinol Metab; 2003 Jul; 88(7):3090-8. PubMed ID: 12843148
[TBL] [Abstract][Full Text] [Related]
38. Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study.
Fredstorp L; Kutz K; Werner S
Clin Endocrinol (Oxf); 1994 Jul; 41(1):103-8. PubMed ID: 8050122
[TBL] [Abstract][Full Text] [Related]
39. Investigation into the efficacy and safety of octreotide LAR in Japanese patients with acromegaly: Shizuoka study.
Oki Y; Inoue T; Imura M; Tanaka T; Genma R; Iwabuchi M; Hataya Y; Matsuzawa Y; Iino K; Nishizawa S; Nakamura H
Endocr J; 2009; 56(9):1095-101. PubMed ID: 19755754
[TBL] [Abstract][Full Text] [Related]
40. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.
Mercado M; Borges F; Bouterfa H; Chang TC; Chervin A; Farrall AJ; Patocs A; Petersenn S; Podoba J; Safari M; Wardlaw J;
Clin Endocrinol (Oxf); 2007 Jun; 66(6):859-68. PubMed ID: 17465997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
